INFORMAZIONI PERSONALI

Pierfausto Seneci

Piazza Einaudi 3, 25015 Desenzano del Garda (BS), Italia
+39-02-50314060 +39-320-6647631
pierfausto.seneci@unimi.it

Sesso M | Data di nascita 09/03/1960 | Nazionalità Italiana

ESPERIENZA PROFESSIONALE

(2011 - OGGI) **PROFESSORE ASSOCIATO – TEMPO PIENO**
UNIVERSITA' DEGLI STUDI DI MILANO, DIPARTIMENTO DI CHIMICA
▪ DIDATTICA, RICERCA DI LABORATORIO – SETTORE CHIMICO FARMACEUTICO
Attività o settore FARMACEUTICO – ONCOLOGIA, CNS, ANTIBATTERICO

(2003 - 2011) **PROFESSORE ASSOCIATO – TEMPO DEFINITO**
UNIVERSITA' DEGLI STUDI DI MILANO, DIPARTIMENTO DI CHIMICA
▪ DIDATTICA, RICERCA DI LABORATORIO – SETTORE CHIMICO FARMACEUTICO
Attività o settore FARMACEUTICO – ONCOLOGIA, CNS, ANTIBATTERICO

(2015 - 2018) **CONSULENTE R&D**
PROMIDIS SRL, MILANO
▪ GESTIONE PROGETTI R&D, BUSINESS DEVELOPMENT
Attività o settore FARMACEUTICO – CHIMICA MEDICINALE

(2006 - 2015) **CONSULENTE R&D**
CISI SCRL, MILANO
▪ GESTIONE PROGETTI R&D, BUSINESS DEVELOPMENT
Attività o settore FARMACEUTICO – CHIMICA MEDICINALE

(2005 - 2008) **CONSULENTE R&D-BUSINESS DEVELOPMENT**
NIKEM RESEARCH SRL, BARANZATE (MI)
▪ GESTIONE PORTAFOGLIO CLIENTI, BUSINESS DEVELOPMENT
Attività o settore FARMACEUTICO – DRUG DISCOVERY

(2003 - 2005) **CONSULENTE R&D-BUSINESS DEVELOPMENT**
SIRENADE PHARMA, MONACO DI BAVIERA (D)
▪ GESTIONE DELL'AZIENDA, FINANCING, R&D
Attività o settore FARMACEUTICO - CNS

(2000 - 2003) **CHIEF SCIENTIFIC OFFICER**
NAD AG, MONACO DI BAVIERA (D)
▪ GESTIONE PROGETTI R&D, MANAGEMENT
Attività o settore FARMACEUTICO - CNS

(1997 - 2000) **DIRETTORE DIPARTIMENTO**

GLAXOWELLCOME, VERONA

▪ GESTIONE PROGETTI R&D, MANAGEMENT

Attività o settore FARMACEUTICO – CNS, ANTIBATTERICO

(1996 -1997) **CAPO LABORATORIO**

SMITHKLINE BEECHAM, RENNES (F)

▪ GESTIONE PROGETTI R&D, MANAGEMENT

Attività o settore FARMACEUTICO – NEUROLOGIA, CV

(1995) **VISITING SCIENTIST**

SELECTIDE, TUCSON (USA)

▪ CHIMICA COMBINATORIALE, HTS

Attività o settore FARMACEUTICO – TECNOLOGIE HIGH THROUGHPUT

(1987 – 1992, 1994) **SCIENTIST, SENIOR SCIENTIST**

MARION MERRELL DOW, GERENZANO (VA)

▪ SINTESI CHIMICA, CHIMICA COMPUTAZIONALE

Attività o settore FARMACEUTICO – ANTIBATTERICO, ANTIVIRALE

(1993) **VISITING SCIENTIST**

MARION MERRELL DOW, STRASBURGO (F)

▪ SINTESI CHIMICA

Attività o settore FARMACEUTICO - NEUROLOGIA

(1986) **SCIENTIST**

PIERREL, MILANO

▪ SINTESI CHIMICA

Attività o settore FARMACEUTICO - ANTIINFIAMMATORI

ISTRUZIONE E FORMAZIONE

(1978 - 1983) **DIPLOMA DI LAUREA IN CHIMICA PURA, 110/110 summa cum laude**

UNIVERSITA' DEGLI STUDI DI PAVIA, ITALIA - COLLEGIO GHISLIERI

▪ CHIMICA ORGANICA, CHIMICA MEDICINALE

(1973 - 1978) **DIPLOMA DI LICEO SCIENTIFICO**

LICEO SCIENTIFICO G. CALINI, BRESCIA, ITALIA

▪ MATERIE SCIENTIFICHE ED UMANISTICHE

COMPETENZE PERSONALI

Lingua madre: ITALIANA

Altre lingue

	COMPRENSIONE		PARLATO		PRODUZIONE SCRITTA
	Ascolto	Lettura	Interazione	Produzione orale	
INGLESE	OTTIMO	OTTIMO	OTTIMO	OTTIMO	OTTIMO

	LIVELLO C2				
FRANCESE	OTTIMO	OTTIMO	OTTIMO	OTTIMO	BUONO
	LIVELLO C2				
TEDESCO	BUONO	BUONO	BUONO	BUONO	BUONO
	LIVELLO B1				
SPAGNOLO	BUONO	BUONO	BUONO	BUONO	BUONO
	LIVELLO B1				

Competenze comunicative

- possiedo buone competenze comunicative, sia in ambito tecnico-scientifico che di business. Le prime derivano dalla trentennale esperienza di ricerca, che ha visto svariate presentazioni e seminari in ambito nazionale ed internazionale, oltre al compito didattico dell'ultimo decennio. La seconda deriva sia dai ruoli dirigenziali ad alto livello in multinazionali farmaceutiche, che da quelli esecutivi in PMI in Germania, che più recentemente in consulenze di business development per PMI italiane

Competenze organizzative e gestionali

- leadership risorse umane (in passato responsabile di laboratori, dipartimenti o intere PMI, team variabili fra 6 e 50 persone)
- leadership progettuale (in passato responsabile di progetti R&D nazionali ed internazionali per multinazionali del farmaco; più recentemente coinvolgimento, e gestione come responsabile di unità di progetti nazionali/regionali pubblici)

Competenze professionali

- buona padronanza dei processi legati alla sicurezza (sia precedentemente nel privato, che ora nel pubblico)

Competenza digitale

AUTOVALUTAZIONE				
Elaborazione delle informazioni	Comunicazione	Creazione di Contenuti	Sicurezza	Risoluzione di problemi
INTERMEDIO	AVANZATO	BASE	INTERMEDIO	BASE

- buona padronanza degli strumenti della suite per ufficio (elaboratore di testi, foglio elettronico, software di presentazione)

Altre competenze

Esperto tecnico-scientifico per il Tech Transfer a paesi in via di sviluppo, UNIDO (1997-2009). Valutatore MIUR (Progetti PON-POR-PRIN) dal 2012. Valutatore Regioni Sardegna, Piemonte, Puglia, Campania, Lazio dal 2010. Esperto Disciplinare ANVUR dal 2017.

Patente di guida

B

ULTERIORI INFORMAZIONI

Pubblicazioni

1. A. Coda, G. Desimoni, A. Invernizzi, P.P. Righetti, **P. Seneci** and G.F. Tacconi, *Copper (II) in organic synthesis II. A stereocontrolled route to alkylprolines*, Gazz. Chim. Ital. **115** (1985), 111-117.
2. A. Coda, G. Desimoni, M. Pappalardo, P.P. Righetti, **P. Seneci**, G.F. Tacconi and R. Oberti, *Copper (II) in organic synthesis IV. Reaction of the copper (II) acetate complex of isatin-3-arylhydrazones with dimethylacetylenedicarboxylate*, Tetrahedron **41** (1985), 2545-2555.
3. C. Fuganti, P. Grasselli, **P. Seneci**, S. Servi and P. Casati, *Immobilized benzylpenicillinacylase: application to the synthesis of optically active forms of carnitine and propranolol*, Tetrahedron Lett. **27** (1986), 2061-2062.
4. C. Fuganti, P. Grasselli, **P. Seneci** and P. Casati, *Further information on the steric course on the baker's yeast reduction of 4-substituted 3-oxobutanoates*, Tetrahedron Lett. **27** (1986), 5275-5276.
5. **P. Seneci**, A. Trani, P. Ferrari, R. Scotti and R. Ciabatti, *Synthesis and biological activity of O56 substituted carboxyesters and carboxyamides of teicoplanin aglycone*, J. Antibiotics **45** (1992), 1633-1644.
6. E. Sarubbi, **P. Seneci**, M.R. Angelastro, N.P. Peet, M. Denaro and K. Islam, *Peptide aldehydes as inhibitors of HIV proteases*, FEBS Letters **319** (1993), 253-256
7. **P. Seneci**, M. Caspani, F. Ripamonti and R. Ciabatti, *Synthesis and antimicrobial activity of oxazolidin-2-ones and related heterocycles*, J. Chem. Soc. Perkin Trans. I (1994), 2345-2351.
8. G. Ranaldi, **P. Seneci**, W. Guba, K. Islam and Y. Sambuy, *Transport of the antibacterial agent oxazolidin-2-one and derivatives across intestinal (Caco-2) and renal (MDCK) epithelial cell lines*, Antimicrob. Agents Chemother. **40** (1996), 652-658.
9. **P. Seneci**, C. Sizemore, K. Islam and P. Kocis, *Combinatorial chemistry and natural products. Teicoplanin aglycone as a molecular scaffold for solid phase synthesis of combinatorial libraries*, Tetrahedron Lett. **37** (1996), 6319-6322.
10. C. Sizemore, **P. Seneci**, P. Kocis, K.F. Wertman and K. Islam, *Combinatorial chemistry and natural products. Determination of the biological activity of on bead, double cleavable teicoplanin aglycone (TD)*, Protein and Peptide Letters, **3** (1996), pp.253-260.
11. **P. Seneci**, M. Caspani, F. Monti, L. Carrano, S. Lociuro and R. Ciabatti, *Synthesis of 2,5- and 2,4-cyclohexadiene-1,3-dicarboxylates via reductive alkylations of isophthalates*, Synth. Commun. **27** (1997), 795-809.
12. **P. Seneci**, I. Leger, M. Souchet and G. Nadler, *Stereoselective alkenylation of aldehydes with phosphorus carbanions: preparation of E- and Z-2-alkoxy- and 2-aryloxy-2-alkenoates*, Tetrahedron **53** (1997), 17097-17114.
13. **P. Seneci**, M. Caspani, F. Monti, L. Carrano and S. Lociuro, *Allylic functionalization of 2,5- and 2,4-cyclohexadiene-1,3-dicarboxylates*, Synth. Commun. **28** (1998), 2097-2123.
14. M. Panunzio, M. Villa, A. Missio, T. Rossi and **P. Seneci**, *Solution phase libraries of perhydrooxazin-4-ones*, Tetrahedron Lett. **39** (1998), 6585-6588.
15. R. Ferritto and **P. Seneci**, *High throughput purification methods in combinatorial solution phase synthesis*, Drugs of the Future **23** (1998), 643-654.
16. **P. Seneci**, *Combinatorial chemistry: basic principles and new trends*, La Chimica e l'Industria **80** (1998), 1183-1189.
17. **P. Seneci**, M. Inglesi, M. Nicola, E. Vanotti and G. Resnati, *Synthesis of mono- and disubstituted 1H-imidazo[1,2-b]pyrazoles*, Synth. Commun. **29** (1999), 311-341.
18. **P. Seneci**, *Direct deconvolution techniques for pool libraries of small organic molecules*, in "Combinatorial Chemistry and Combinatorial Technologies: Principles, Methods and Applications" (Eds. S. Miertus, G. Fassina), Marcel Dekker, Inc., New York (1999), 91-125.
19. **P. Seneci**, *Encoding techniques for pool libraries of small organic molecules*, in "Combinatorial Chemistry and Combinatorial Technologies: Principles, Methods and Applications" (Eds. S. Miertus, G. Fassina), Marcel Dekker, Inc., New York (1999), 127-167.
20. R. Ferritto, E. de Magistris, A. Missio, A. Paio and **P. Seneci**, *Solution phase combinatorial libraries of small organic molecules*, in "Combinatorial Chemistry and

Combinatorial Technologies: Principles, Methods and Applications" (Eds. S. Miertus, G. Fassina), Marcel Dekker, Inc., New York (1999), 53-90.
21. S. Maiorana, **P. Seneci**, T. Rossi, C. Baldoli, M. Ciraco, E. de Magistris, E. Licandro, A. Papagni and S. Provera, *Synthesis of polymer-bound Fischer chromium alkoxy and aminocarbene complexes*, Tetrahedron Lett. **40** (1999), 3635-3638.
22. A. Paio, A. Zaramella, R. Ferritto, N. Conti, C. Marchioro and **P. Seneci**, *Solid-supported benzotriazoles: synthetic auxiliaries and traceless linkers for the combinatorial synthesis of amine libraries*, J. Comb. Chem. **1** (1999), 317-325.
23. **P. Seneci**, *New technologies in the third millennium. Applications in the discovery of new drugs and in catalysis,* La Chimica e l'Industria **81** (1999), 1263-1264.
24. G. Faita, A. Paio, P. Quadrelli, F. Rancati and **P. Seneci**, *(4S)-p-hydroxybenzyl-1,3-oxazolidin-2-one as solid supported chiral auxiliary in asymmetric 1,3-dipolar cycloadditions*, Tetrahedron Lett. **41** (2000), 1265-1269.
25. A. Missio, C. Marchioro, T. Rossi, M. Panunzio, S. Selva and **P. Seneci**, *Polymer-supported silyl cyanide and silyl azide: useful reagents for solid-phase applications*, Biotechnol. Bioengineering **71** (2000), 38-43.
26. M. Rabinowitz, **P. Seneci**, T. Rossi, M. Dal Cin and M. Deal, *Solid-Phase/Solution-Phase Combinatorial Synthesis of Neuroimmunophilin Ligands*, Bioorg. Med. Chem. Lett. **10** (2000), 1007-1010.
27. G. Kennedy, M. Viziano, J. A. Winders, P. Cavallini, M. Gevi, F. Micheli, P. Rodegher, **P. Seneci** and A. Zumerle, *Studies on the novel anti-staphylococcal compound nematophin*, Bioorg. Med. Chem. Lett. **10** (2000), 1751-1754.
28. F. Gennari, **P. Seneci** and S. Miertus, *Application of Combinatorial Technologies for Catalyst Design and Development*, Catal. Rev. – Sci. Eng. **42** (2000), 385-402.
29. S. Maiorana, C. Baldoli, E. Licandro, L. Casiraghi, E. de Magistris, A. Paio, S. Provera and **P. Seneci**, *New Polymer-Bound Haloarene Chromium Dicarbonyl Isocyanide Complexes: A Successful Study Validating Their Use in Solid-Phase Synthesis*, Tetrahedron Letters **41** (2000), 7271-7275.
30. S. Miertus, G. Fassina and **P. Seneci**, *Concepts of Combinatorial Chemistry and Combinatorial Technologies*, Chemicke Listy **94** (2000), 1104-1110.
31. S. Miertus, G. Fassina and **P. Seneci**, *Basic concepts of combinatorial chemistry and combinatorial technologies*, in "Proceedings of the Southeast Asian Regional Workshop on Combinatorial Chemistry and Combinatorial Technologies" (Eds. S. Miertus, G. Fassina, **P. Seneci** and C. Calanasan), ICS-UNIDO Publications, Manila, Philippines (2000), 1-33.
32. **P. Seneci** and A. Paio, *Solid-Phase Synthesis of Substituted Amine Libraries*, in "Protocols in Combinatorial Chemistry and Combinatorial Technologies" (Eds. G. Fassina and S. Miertus), ICS-UNIDO Publications, Vienna, Austria (2000), 6.1-6.12.
33. **P. Seneci** and A. Missio, *Solution-Phase Synthesis of a Discrete Library of Heterocycles*, in "Protocols in Combinatorial Chemistry and Combinatorial Technologies" (Eds. G. Fassina and S. Miertus), ICS-UNIDO Publications, Vienna, Austria (2000), 7.1-7.9.
34. **P. Seneci** and S. Miertus, *Combinatorial Chemistry and High-Throughput Screening in Drug Discovery: Different Strategies and Formats*, Molecular Diversity **5** (2000), 75-89.
35. F. Micheli, F. Degiorgis, A. Feriani, A. Paio, A. Pozzan, P. Zarantonello and **P. Seneci**, *A Combinatorial Approach to [1,5]Benzothiazepine Derivatives as Potential Antibacterial Agents*, J. Comb. Chem. **3** (2001), 224-228.
36. **P. Seneci**, *New Trends in Combinatorial Technologies*, in "Trends and Applications of Combinatorial Chemistry and Molecular Design", ICS-UNIDO Publications, Vienna, Austria (2001), 27-32.
37. **P. Seneci** and S. Miertus, *Natural Products and Combinatorial Technologies: Basic Principles and New Trends*, in "Trends and Applications of Combinatorial Chemistry and Molecular Design", ICS-UNIDO Publications, Vienna, Austria (2001), 59-78.
38. **P. Seneci** and S. Miertus, *Combinatorial Technologies and Materials Science: Synthesis and Screening of Materials Libraries*, in "Trends and Applications of Combinatorial Chemistry and Molecular Design", ICS-UNIDO Publications, Vienna, Austria (2001), 79-92.
39. A. Paio, R. Ferritto Crespo, **P. Seneci** and M. Ciraco', *Solid-supported benzotriazoles: Synthetic Auxiliaries and Traceless Linkers for the Combinatorial Synthesis of*

Unsymmetrical Ureas, J. Comb. Chem. **3** (2001), 354-359.
40. A. Zaramella, N. Conti, M. Dal Cin, A. Paio, **P. Seneci** and S. Gehanne, *Dansyl and Dabsyl Analytical Constructs as Tools for the Accurate Estimation of Compounds in Solid-Phase Synthesis*, J. Comb. Chem. **3** (2001), 410-420.
41. A. Bernardi, D. Arosio, L. Manzoni, F. Micheli, A. Pasquarello and **P. Seneci**, *Stereoselective Synthesis of Conformationally Constrained Cyclohexanediols: a Set of Molecular Scaffolds for the Synthesis of Glycomimetics*, J. Org. Chem. **66** (2001), 6209-6216.
42. G. Faita, A. Paio, P. Quadrelli, F. Rancati and **P. Seneci**, *Solid Supported Chiral Auxiliary in Asymmetric Synthesis. Part 2. Catalysis of 1,3-Dipolar Cycloadditions by Mg(II) Cation*, Tetrahedron **57** (2001), 8313-8322.
43. **P. Seneci**, *Direct deconvolution techniques for pool libraries of small organic molecules*, J. Recept. Sign. Transduct. Res. **21** (2001), 377-408.
44. **P. Seneci**, *Encoding techniques for pool libraries of small organic molecules*, J. Recept. Sign. Transduct. Res. **21** (2001), 409-445.
45. **P. Seneci**, *Chemical diversity as a driving force to design and realize synthetic strategies leading to combinatorial libraries for lead discovery and lead optimization,* in "Trends in Drug Research III, Pharmacochemistry Library", Volume **32** (Ed. H. van der Goot), Elsevier, Amsterdam (2002), 147-160.
46. E. La Porta, U. Piarulli, F. Cardullo, A. Paio, S. Provera, **P. Seneci** and C. Gennari, *Cyclative Cleavage Via Solid-Phase Supported Stabilized Sulfur Ylides: Synthesis of Macrocyclic Lactones*, Tetrahedron Lett. **43** (2002), 761-766.
47. G. Faita, M. Mella, A. Mortoni, A. Paio, P. Quadrelli and **P. Seneci**, *Solid Phase 1,3-Dipolar Cycloadditions: Synthesis of 5-Membered Heterocycles*, Eur. J. Org. Chem. **57** (2002), 1175-1183.
48. **P. Seneci**, J. Miertus, A. Amoroso and S. Miertus, *Synergies between chemistry, proteomics and genomics*, La Chimica e l'Industria **84** (2002), 13-15.;
49. S. Gehanne, E. Grandini, A. Paio, G. Reginato and **P. Seneci**, *A New Analytical Method for Loading Estimation of Amino Acids on Resin Support*, Tetrahedron Letters **44** (2003), 1867-1870.
50. F. Peri, F. Nicotra, C. P. Lesile, F. Micheli, **P. Seneci** and C. Marchioro, *D-glucose as a regioselectively addressable scaffold for combinatorial chemistry on solid phase*, J. Carbohydrate Chem. **22** (2003), 57-71.
51. **P. Seneci**, *Once upon a time there was combinatorial chemistry….*, Chimica Oggi **21** (2003), 67-69.
52. **P. Seneci**, *Combinatorial Chemistry and Combinatorial Technologies*, in "Molecular Modelling and Computer-Assisted Combinatorial Chemistry", ICS-UNIDO Publications, Vienna, Austria (2003).
53. **P. Seneci**, *Combinatorial Chemistry and Combinatorial Technologies: A Case Study*, in "Molecular Modelling and Computer-Assisted Combinatorial Chemistry", ICS-UNIDO Publications, Vienna, Austria (2003).
54. **P. Seneci**, *Chimica Combinatoriale*, in "Enciclopedia del Novecento. Supplemento. dal XX al XXI Secolo: Problemi e Prospettive", Enciclopedia Italiana Treccani, Roma, Italy (2003).
55. **P. Seneci**, *Polymer-supported trimethylsilyl cyanide*, in "Electronic encyclopedia of reagents for organic synthesis" (Editor-in-Chief L. A. Paquette), John Wiley and Sons Ltd (2003).
56. C. Baldoli, S. Maiorana, E. Licandro, L. Casiraghi, G. Zinzalla, **P. Seneci**, E. de Magistris, A. Paio and C. Marchioro, *Polymer-supported haloarene chromium dicarbonyl isonitrile complexes: a study of their synthesis and reactivity*, J. Comb. Chem. **5** (2003), 809-813.
57. S. Castoldi, M. Cravini, F. Micheli, E. Piga, G. Russo, **P. Seneci** and L. Lay, *Solution synthesis of two orthogonally protected lactosides as tetravalent disaccaride-based scaffolds*, Eur. J. Org. Chem. (2004), 2853-2862.
58. W. Froehner, B. Monse, T. Braxmeier, L. Casiraghi, H. Sahagun and **P. Seneci**, *Regiospecific synthesis of mono-N-substituted indolopyrrolocarbazoles*, Org. Lett. **7** (2005), 4573-4576.
59. S. LeCorre, H.W. Klafki, N. Plesnila, G. Huebinger, A. Obermeier, H. Sahagun, B. Monse, **P. Seneci**, J. Lewis, J. Eriksen, C. Zehr, M. Yue, E. McGowan, D.W. Dickson,

M. Hutton and H.M. Roder, *An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice*, Proc. Natl. Acad. Sci. USA **103** (2006), 9673-9678.

60. **P. Seneci**, *Combinatorial Chemistry*, in "Comprehensive Medicinal Chemistry II" (Editors-in Chief J. Taylor and L. Triggs), Elsevier Ltd, Oxford (2006), 697-760.
61. E. Mastrangelo, F. Cossu, M. Milani, G. Sorrentino, D. Lecis, D. Delia, L. Manzoni, C. Drago, **P. Seneci**, C. Scolastico, V. Rizzo and M. Bolognesi, *Targeting the X-Linked Inhibitor of Apoptosis Protein (XIAP) through 4-substituted azabicyclo[5.3.0]alkane Smac mimetics. Structure, activity and recognition principles*, J. Mol. Biol. **384** (2008), 673-689.
62. F. Cossu, E. Mastrangelo, M. Milani, G. Sorrentino,D. Lecis, D. Delia, L. Manzoni, **P. Seneci**, C. Scolastico and M. Bolognesi, *Designing Smac-mimetics as antagonists of XIAP, cIAP1 and cIAP2*, Biochem. Biophys. Res. Commun. **378** (2009), 162-176.
63. F. Cossu, M. Milani, E. Mastrangelo, P. Vachette, F. Servida, D. Lecis, G. Canevari, D. Delia, C. Drago, V. Rizzo, L. Manzoni, **P. Seneci**, C. Scolastico and M. Bolognesi, *Structural Basis for Bivalent Smac-Mimetics Recognition in the IAP Protein Family,* J. Mol. Biol. **392** (2009), 630-644.
64. **P. Seneci**, *Fragment-based Drug Discovery–CHI's fourth annual meeting*, IDrugs **12** (2009), 353-357.
65. **P. Seneci**, *Kinase inhibitor chemistry: Charting the chemical space-CHI's fourth annual meeting*, IDrugs **12** (2009), 358-362.
66. **P. Seneci**, A. Bianchi, C. Battaglia, L. Belvisi, M. Bolognesi, A. Caprini, F. Cossu, E. de Franco, M. de Matteo, D. Delia, C. Drago, A. Khaled, D. Lecis, L. Manzoni, M. Marizzoni, E. Mastrangelo, M. Milani, I. Motto, D. Potenza, V. Rizzo, F. Servida, E. Turlizzi, M. Varrone, F. Vasile and C. Scolastico, *Rational design, synthesis and characterization of potent, non-peptidic Smac mimics/XIAP inhibitors as pro-apoptotic agents in cancer therapy*, Bioorg. Med. Chem. **17** (2009), 5834-5856.
67. D. Lecis, C. Drago, L. Manzoni, **P. Seneci**, C. Scolastico, E. Mastrangelo, M. Bolognesi, A. Anichini, H. Kashkar, H. Walczak and D. Delia, *Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and bortezomib*, British J. Cancer **102** (2010), 1707-1716.
68. W. Hatton, D. Arosio, M. Re, D. Giudici, A. Bernardi and **P. Seneci**, *Synthesis of nonglycosidic nucleo base-sugar mimetics*, Comptes Rendues Chimie **13** (2010), 1284-1300.
69. **P. Seneci**, *Anti-inflammatories: small molecule approaches-CHI's inaugural event*, IDrugs **13** (2010), 379-382.
70. C. Podlipnik, F. Tutino, A. Bernardi and **P**. **Seneci**, *DFG-in and DFG-out Homology Models of TrkB kinase receptor: Induced–fit and Ensemble docking*, Journal of Molecular Graphics and Modelling **29** (2010), 309-320.
71. F. Cossu, F. Malvezzi, G. Canevari, E. Mastrangelo, D. Lecis, D. Delia, **P. Seneci**, C. Scolastico, M. Bolognesi and M. Milani, *Recognition of Smac-mimetic compounds by the BIR domain of cIAP1*, Protein Science **19** (2010), 2418-2429.
72. V. Frecer, **P. Seneci** and S. Miertus, *Computer-assisted combinatorial design of bicyclic thymidine analogs as inhibitors of Mycobacterium tuberculosis thymidine monophosphate kinase*, J. Comput.-Aided Mol. Design **25** (2011), 31-49.
73. F. Servida, D. Lecis, C. Scavullo, C. Drago, **P. Seneci**, C. Carlo-Stella, L. Manzoni, E. Polli, G. Lambertenghi Deliliers, D. Delia and F. Onida, *Novel second mitochondria-derived activator of caspases (Smac) mimetic compounds sensitize human leukemic cell lines to conventional chemotherapeutic drug-induced and death receptor-mediated apoptosis*, Invest. New Drugs **29** (2011), 1264-1275.
74. **P. Seneci**, *Trialkylsilyl cyanide*, *polymer-supported,* in "Handbook of reagents for organic synthesis: Reagents for silicon-mediated organic synthesis" (Editor-in-Chief P. Fuchs), John Wiley and Sons Ltd. (2011), 494-496.
75. A. Bianchi, M. Ugazzi, L. Ferrante, D. Lecis, C. Scavullo, E. Mastrangelo and **P. Seneci**, *Rational design, synthesis and characterization of potent, drug-like monomeric Smac mimics as pro-apoptotic anticancer agents*, Bioorg. Med. Chem. Lett. **22** (2012), 2204-2208.
76. J. Kongkamnerd, L. Cappelletti, A. Prandi, **P. Seneci**, T. Rungrotmongkol, N. Jongaroonngamsang, P. Rojsittishak, V. Frecer, A. Milani, G. Cattoli, C.

Terregino, I. Capua, L. Beneduce, A. Gallotta, P. Pengo, G. Fassina, S. Miertus, W. De-Eknamkul. *Synthesis and in vitro study of novel neuraminidase inhibitors against avian influenza virus*. Bioorg. Med. Chem. **20** (2012), 2152-2157.
77. D. Potenza, L. Belvisi, F. Vasile, E. Moroni, F. Cossu, **P. Seneci**. *A NMR and computational study of Smac mimics targeting both the BIR2 and BIR3 domains in XIAP protein*. Org. Biomol. Chem. **10** (2012), 3278-3287.
78. **P. Seneci**. *Small molecules as pro-apoptotic cancer agents*. Pharmac. Patent Analyst. **1** (2012), 483-505.
79. L. Manzoni, L. Belvisi, A. Bianchi, A. Conti, C. Drago, M. de Matteo, L. Ferrante, E. Mastrangelo, P. Perego, D. Potenza, C. Scolastico, F. Servida, G. Timpano, F. Vasile, V. Rizzo, **P. Seneci**. *Homo- and heterodimeric Smac mimetics/IAP inhibitors as in vivo-active pro-apoptotic agents. Part I: Synthesis*. Bioorg. Med. Chem. **20** (2012), 6687-6708.
80. D. Lecis, E. Mastrangelo, L. Belvisi, M. Bolognesi, M. Civera, F. Cossu, M. De Cesare, D. Delia, C. Drago, G. Manenti, L. Manzoni, M. Milani, E. Moroni, P. Perego, D. Potenza, V. Rizzo, C. Scavullo, C. Scolastico, F. Servida, F. Vasile, **P. Seneci**. *Dimeric Smac mimetics/IAP inhibitors as in vivo-active pro-apoptotic agents. Part II: Structural and biological characterization.* Bioorg. Med. Chem. **20** (2012), 6709-6723.
81. F. Cossu, M. Milani, P. Vachette, F. Malvezzi, S. Grassi, D. Lecis, D. Delia, C. Drago, **P. Seneci**, M. Bolognesi, E. Mastrangelo. *Structural insight into inhibitor of apoptosis proteins recognition by a potent divalent Smac-mimetic*. PLoS One **7** (2012), e49527.
82. **P. Seneci**, V. Frecer, S. Miertus. *Computer-assisted design of drug-like libraries*. RSC Discovery Series **23** (2012), 372-398.
83. C. Scavullo, F. Servida, Federica, D. Lecis, F. Onida, C. Drago, L. Ferrante, **P. Seneci**, W. Barcellini, M. Lionetti, K. Todoerti, A. Neri, D. Delia, G. Lambertenghi Deliliers. *Single-agent Smac-mimetic compounds induce apoptosis in B chronic lymphocytic leukaemia (B-CLL)*. Leukemia Res. **37** (2013), 809-815.
84. D. Lecis, M. De Cesare, P. Perego, A. Conti, E. Corna, C. Drago, **P. Seneci**, H. Walczak, M.P. Colombo, D. Delia, S. Sangaletti. *Smac mimetics induce inflammation and necrotic tumour cell death by modulating macrophage activity*. Cell Death Dis. **4** (2013), e920.
85. L. Gatti, M. De Cesare, E. Ciusani, E. Corna, N. Arrighetti, D. Cominetti, L. Belvisi, D. Potenza, E. Moroni, F. Vasile, D. Lecis, D. Delia, V. Castiglioni, E. Scanziani, **P. Seneci**, N. Zaffaroni, P. Perego. *Antitumor activity of a novel homodimeric SMAC mimetic in ovarian carcinoma*. Mol. Pharm. **11** (2014), 283-293.
86. **P. Seneci**, M. Rizzi, L. Ballabio, D. Lecis, A. Conti, C. Carrara, E. Licandro. *SPION-Smac mimetic nano-conjugates: Putative pro-apoptotic agents in oncology*. Bioorg. Med. Chem. Lett. **24**, (2014) 2374-2378.
87. M. Mingozzi, L. Manzoni, D. Arosio, A. Dal Corso, M. Manzotti, F. Innamorati, L. Pignataro, D. Lecis, D. Delia, **P. Seneci**, C. Gennari. *Synthesis and biological evaluation of dual action cyclo-RGD/SMAC mimetic conjugates targeting αvβ3/αvβ5 integrins and IAP proteins*. Org. Biomol. Chem. 12 (2014), 3288-3302.
88. T. Udommaneethanakit, T. Rungrotmongkol, V. Frecer, **P. Seneci**, S. Miertus, U. Bren. *Drugs against avian influenza A virus: Design of novel sulfonate inhibitors of neuraminidase N1*. Curr. Pharm. Des. **20** (2014), 3478-3487.
89. **P. Seneci**, G. Fassina, V. Frecer, S. Miertus. *The effects of combinatorial chemistry and technologies on drug discovery and biotechnology - a mini review.* Nova Biotechnol. Chimica 13 (2014), 87-108.
90. **P. Seneci**. *Targets and small molecules against tauopathies. Part 1: From genes to soluble, aggregation-prone tau proteins*, in "Drug Design and Discovery in Alzheimer's Disease", Elsevier, Waltham, MA (2014), 643-715.
91. D. Lattuada, C. Casnici, K. Crotta, **P. Seneci**, C. Corradini, M. Truzzi, F. Ingegnoli, O. Marelli. *Proapoptotic activity of a monomeric Smac mimetic on human fibroblast-like synoviocytes from patients with rheumatoid arthritis*. Inflammation **38** (2015), 102-109.
92. A. Conti, M.T. Majorini, R. Elliott, A. Ashworth, C.J. Lord, C. Cancelliere, A.

Bardelli, **P. Seneci**, H. Walczak, D. Delia, D. Lecis. *Oncogenic KRAS sensitizes premalignant, but not malignant cells, to Noxa-dependent apoptosis through the activation of the MEK/ERK pathway*. Oncotarget **6** (2015), 10994-11008.

93. V.G. D'Agostino, P. Lal, B. Mantelli, C. Tiedje, C. Zucal, N. Thongon, M. Gaestel, E. Latorre, L. Marinelli, **P. Seneci**, M. Amadio, A. Provenzani. *Dihydrotanshinone-I interferes with the RNA-binding activity of HuR affecting its post-transcriptional function*. Sci. Reports **5** (2015), 16478.
94. D. Lattuada, R. Gualtierotti, K. Crotta, **P. Seneci**, F. Ingegnoli, C. Corradini, R. Viganò, O. Marelli, C. Casnici. *Smac127 has proapoptotic and anti-inflammatory effects on rheumatoid arthritis fibroblast-like synoviocytes*. Mediators Inflamm. **2016**, (2016), 6905678.
95. L. Manzoni, D. Gornati, M. Manzotti, S. Cairati, A. Bossi, D. Arosio, D. Lecis, **P. Seneci**. *Dual action Smac mimetics-zinc chelators as pro-apoptotic antitumoral agents*. Bioorg. Med. Chem. Lett. **26** (2016), 4613-4619.
96. L. Manzoni, A. Samela, S. Barbini, S. Cairati, M. Penconi, D. Arosio, D. Lecis, **P. Seneci**. *4-Connected azabicyclo[5.3.0]decane Smac mimetics-Zn^{2+} chelators as dual action antitumoral agents*. Bioorg. Med. Chem. Lett. **27** (2017), 2336-2344.
97. P. Lal, L. Cerofolini, V.G. D'Agostino, C. Zucal, C. Fuccio, I. Bonomo, E. Dassi, S. Giuntini, D. Di Maio, V. Vishwakarma, R. Preet, S.N. Williams, M.S. Fairlamb, R. Munk, E. Lehrmann, K. Abdelmohsen, S.R. Elezgarai, C. Luchinat, E. Novellino, A. Quattrone, E. Biasini, L. Manzoni, M. Gorospe, D.A. Dixon, **P. Seneci**, L. Marinelli, M. Fragai, A. Provenzani. *Regulation of HuR structure and function by dihydrotanshinone-I*. Nucl. Acid Res. **45** (2017), 9514-9527.
98. L. Manzoni; C. Zucal; D. Di Maio.; V.G. D'Agostino.; N. Thongon; I. Bonomo.; P. Lal; M. Miceli; V. Baj; M. Brambilla; L. Cerofolini; S. Elezgarai; E. Biasini; C. Luchinat; E. Novellino; M. Fragai; L. Marinelli; A. Provenzani; **P**. **Seneci**. *Interfering with HuR–RNA interaction: design, synthesis and biological characterization of tanshinone mimics as novel, effective HuR inhibitors*. J. Med. Chem. **61** (2018), 1483-1498.
99. Corti, A.; Milani, M.; Lecis, D.; Seneci, P.; de Rosa, M.; Mastrangelo, E.; Cossu, F. *Structure-based design and molecular profiling of Smac mimetics selective for cellular IAPs*. FEBS Lett. **285** (2018), 3286-3298.
100. Fumagalli, G.; Polito, L.; Colombo, E.; Foschi, F.; Christodoulou, M.S.; Galeotti, F.; Perdicchia, D.; Bassanini, I.; Riva, S.; **Seneci, P.**; Garcia-Argaez, A.; Dalla Via, L.; Passarella, D. *Self-assembling releasable thiocolchicine-diphenylbutenylaniline conjugates*. ACS Med. Chem. Lett. **10** (2019), 627-632.
101. Bencheva, L.I.; De Matteo, M.; Ferrante, L.; Ferrara, M.; Prandi, A.; Randazzo, P.; Ronzoni, S.; Sinisi, R.; **Seneci, P.**; Summa, V.; Gallo, M.; Veneziano, M.; Cellucci, A.; Mazzocchi, N.; Menegon, A.; Di Fabio, R. *Identification of isoform 2 Acid-Sensing Ion Channel Inhibitors as tool compounds for target validation studies in CNS*. ACS Med. Chem. Lett. **10** (2019), 611-614.
102. Spinelli, A.; Girelli, M.; Arosio, D.; Polito, L.; Podini, P.; Martino, G.; **Seneci, P**.; Muzio, L.; Menegon, A. *Intracisternal delivery of PEG-coated gold nanoparticles results in high brain penetrance and long-lasting stability*. J. Nanobiotechnology **17** (2019), 49.
103. Palomo-Irigoyen, M.; Pérez-Andrés, E.; Iruarrizaga-Lejarreta, M.; Barreira-Manrique, A.; Tamayo-Caro, M.; Vila-Vecilla, L.; Moreno-Cugnon, L.; Beitia, N.; Medrano, D.; Fernández-Ramos, D.; Lozano, J.J.; Okawa, S.; Lavín, J.L.; Martín-Martín, N.; Sutherland, J.D.; Guitiérez de Juan, V.; Gonzalez-Lopez, M.; Macías-Cámara, N.; Mosén-Ansorena, D.; Laraba, L.; Hanemann, C.O.; Ercolano, E.; Parkinson, D.B.; Schultz, C.W.; Araúzo-Bravo, M.J.; Ascensión, A.M.; Gerovska, D.; Iribar, H.; Izeta, A.; Pytel, P.; Krastel, P.; Provenzani, A.; **Seneci, P**.; Carrasco, R.D.; Del Sol, A.; Martinez-Chantar, M.L.; Barrio, R.; Serra, E.; Lazaro, C.; Flanagan, A.M.; Gorospe, M.; Ratner, N.; Carracedo, A.; Aransay, A.M.; Varela-Rey, M.; Woodhoo, A. *HuR/ELAVL1 drives malignant peripheral nerve sheath tumour growth and metastasis*. J. Clin. Invest. **130** (2020), 3848-3864.
104. Muzio, L.; Sirtori, R.; Gornati, D.; Eleuteri, S.; Fossaghi, A.; Brancaccio, D.; Manzoni, L.; Ottoboni, L.; De Feo, L.; Quattrini, A.; Mastrangelo, E.; Sorrentino, L.; Scalone, E.; Comi, G.; Marinelli, L.; Riva, N.; Milani, M.; **Seneci, P**.; Martino, G. *Retromer stabilization results in neuroprotection in a model of Amyotrophic Lateral Sclerosis*. Nat. Commun **11** (2020), 3848.

105. Assoni, G.; Frapporti, G.; Colombo, E.; Gornati, D.; Perez-Carrion, M.D.; Polito, L.; **Seneci, P.; Piccoli,** G.; Arosio, D. *Trehalose-based neuroprotective autophagy inducers*. Bioorg. Med. Chem. Lett. **40** (2021), 127929.
106. Giordano, G.; Biehler-Gomez, L.; Cattaneo, C.; **Seneci, P**.; Di Candia, D. *Detecting drugs in dry bone: a pilot study of skeletal remains with a post-mortem interval over 23 years*. Int. J. Legal Med. **135** (2021), 457-463.
107. D Gornati, R. Ciccone, A. Vinciguerra, S. Ippati, A. Pannaccione, T. Petrozziello, E. Pizzi, A. Hassan, E. Colombo, S. Barbini, M. Milani, C. Caccavone, P. Randazzo, L. Muzio, L. Annunziato, A. Menegon, A. Secondo, E. Mastrangelo, G. Pignataro and **P Seneci**. *Synthesis and characterization of Novel mono- and bis-guanylhydrazones as potent and selective ASIC1 inhibitors able to reduce brain ischemic insult.* J. Med. Chem. **64** (2021), 8333-8353.
108. Antoniou, A.I; Giofrè, S.; Seneci, P.; Passarella, D.; Pellegrino, S. *Stimulus-responsive liposomes for biomedical applications*. Drug Discov. Today 26 (2021), 1794-1824.
109. Russomanno, P.; Assoni, G.; Amato, J.; D'Amore, V.M.; Scaglia, R.; Brancaccio, D.; Pedrini, M.; Polcaro, G.; La Pietra, V.; Orlando, P.; Falzoni, M.; Cerofolini, L.; Giuntini, S.; Fragai, M.; Pagano, B.; Donati, G.; Novellino, E.; Quintavalle, C.; Condorelli, G.; Sabbatino, F.; **Seneci, P**.; Arosio, D.; Pepe, S.; Marinelli, L. *J. Med. Chem*. 64 (2021), 16020-16045.
110. Assoni, G.; La Pietra, V.; Digilio, R.; Ciani, C.; Licata, N.V.; Micaelli, M.; Facen, E.; Tomaszewska, W.; Cerofolini, L.; Pérez-Ràfols, A.; Varela Rey, M.; Fragai, M.; Woodhoo, A.; Marinelli, L.; Arosio, D.; Bonomo, I.; Provenzani, A.; Seneci, P. *HuR-targeted agents: An insight into medicinal chemistry, biophysical, computational studies and pharmacological effects on cancer models*. Adv. Drug Delivery Rev. **181** (2022), 114088.

Libri

1. **P. Seneci**, *Solid Phase Synthesis and Combinatorial Technologies*, 637 pages, J. Wiley and Sons, New York, July 2000.
2. **P. Seneci**, *Molecular Targets in Protein Folding and Neurodegenerative Disease*, 314 pages, Academic Press, San Diego, October 2014.
3. **P. Seneci**, *Chemical Modulators of Protein Folding and Neurodegenerative Disease*, 260 pages, Academic Press, San Diego, January 2015.
4. **P. Seneci**, *Chemical Sciences in Early Drug Discovery*, 194 pages, Elsevier, Amsterdam, June 2018.

Brevetti

1. *WO9011300*, A. Malabarba, **P. Seneci**, J.K. Kettenring and R. Ciabatti, Preparation of new substituted alkylamide derivatives of teicoplanin as antibacterials, 4/10/1990.
2. *EP391077*, A. Trani, P. Ferrari, **P. Seneci** and R. Ciabatti, Preparation of 56 O-alkyl derivatives of aglycones and pseudoaglycones of teicoplanin as antibacterials, 10/10/1990.
3. *WO9624607*, S. Lociuro, **P. Seneci**, E. Restelli and R. Ciabatti, Preparation of basic prolineamide derivatives of GE2270 and GE2270 like antibiotics, 15/8/1996.
4. *EWO9624608*, S. Lociuro, **P. Seneci** and R. Ciabatti, Preparation of basic oxazolineamide derivatives of GE2270 and GE2270 like antibiotics, 15/8/1996.
5. *WO9801423*, C. Farina, S. Gagliardi, E. Consolandi, G. Nadler and **P. Seneci**, 5-indolyl-2,4-pentadienoic acid derivatives useful as inhibitors of bone resorption, 15/1/1998.
6. *WO9801445*, C. Farina, G. Nadler and **P. Seneci**, Indole derivatives for the treatment of osteoporosis, 15/1/1998.
7. WO2003051887, H. Sahagun-Krause, O. Thillaye Du Boullay, V. Thillaye Du Boullay, L. Casiraghi, **P. Seneci**, H.-W. Klafki, T. Braxmeier, S. Mueller, W. Froehner, B.

Monse, S. Gordon and H. Roder, Preparation of N-carbacycle monosubstituted indolocarbazoles for therapeutic use as protein kinase inhibitors, 17/12/2001.

8. WO2004048384, B. Monse, T. Braxmeier, S. Ferrand, S. Gordon, H. Klafki, G. Lahu, H. Roder, H. Sahagun-Krause, **P. Seneci** and O. Thillaye Du Boullay, Preparation of N,N-bridged, nitrogen-substituted carbacyclic indolocarbazoles for use in pharmaceutical compositions as protein kinase inhibitors, 27/11/2002.
9. EP07021843, C. Scolastico, L. Manzoni, **P. Seneci**, L. Belvisi, I. Motto, C. Drago, D. Delia, M. Bolognesi, E. Mastrangelo and M. Milani De Mayo De Mari, New SMAC mimetic compounds as apoptosis inducers, 9/11/2007.
10. WO2013124701, **P. Seneci**, L. Belvisi, F. Cossu, D. Delia, C. Drago, D. Lecis, S. Maiorana, L.P. Manzoni, E. Mastrangelo, M. Milani de Mayo de Mari, P.M.C. Perego, V. Vasile, Preparation of homo- and heterodimeric Smac mimetic compounds as apoptosis inducers, 29/8/2013.
11. WO2015118019 A1, P. Pevarello, S. Lohmer, C. Liberati, **P. Seneci**, C. Pesenti and A. Prandi, Preparation of substituted thiazole derivatives and analogs for use as P2X7 receptor antagonists, 13/8/2015.
12. EP2905282 A1, P. Pevarello, S. Lohmer, C. Liberati, **P. Seneci**, C. Pesenti and A. Prandi, Preparation of substituted thiazole derivatives and analogs for use as P2X7 receptor antagonists, 13/8/2015.
13. WO 2017216732 A1, A. Provenzani, V.G. D' Agostino, N. Thongon, C. Zucal, P. Lal, V. Adami, **P. Seneci**, L. Manzoni, L. Marinelli, E.Novellino, M. Fragai, C. Luchinat, L. Cerofolini, C. Fuccio. Process for the preparation of aza-tanshinone derivatives and their use in therapy. 21/12/2017.
14. WO 2020201326 A1, G. Martino, L. Muzio, N. Riva, D. Gornati, **P. Seneci**, S.C. Eleuteri. Preparation of aminoguanidine hydrazones as retromer stabilizers useful for treating neurological diseases. 01/04/2019.
15. IT 102021000016775 A1, L. Marinelli, D. Arosio, **P. Seneci**. Triazine derivatives for the treatment of tumours and neurodegenerative diseases. 25/06/2021.

Presentazioni a convegni

1. *Natural products as new scaffolds for solid phase synthesis of combinatorial libraries,* in *Combinatorial chemistry: new developments and applications in drug discovery*, Schliersee (Germany), October 16th-18th, 1996.
2. *Combinatorial chemistry and molecular diversity. New horizons for the synthetic chemists*, in *New trends in organic synthesis*, Milan (Italy), November 21st, 1996.
3. *New trends in solution phase combinatorial chemistry*, in *Advanced Course of Medicinal Chemistry and National Seminar for doctorate students*, Urbino (Italy), July 2nd-5th, 1997.
4. *Liquid phase combinatorial chemistry* and *Deconvolution techniques in combinatorial chemistry*, in *Methodologies, applications and economics of combinatorial chemistry and combinatorial technologies*, ICS-UNIDO and Tecnogen SpA, Piana di Monte Verna (Italy), September 8th-19th, 1997.
5. *New strategies in drug discovery*, in *38th AFI Symposium*, Montecatini Terme (Italy), June 3rd-5th, 1998.
6. *The impact of combinatorial technologies in the acceleration of the drug discovery cycle*, in the *9th Workshop in Clinical Pharmacology*, University of Milan, June 9th, 1998.
7. *Trends in Combinatorial Technology* and *A case study of Pharma applications*, in the *Expert Group Meeting on Combinatorial Chemistry, Combinatorial Technologies and Molecular Design*, ICS-UNIDO, Trieste (Italy), June 15th-17th, 1998.
8. *Liquid phase combinatorial chemistry, Deconvolution techniques in combinatorial chemistry, Solid phase combinatorial chemistry* and *Trends in Combinatorial Technology* in the *Workshop on Combinatorial Technologies*, ICS-UNIDO and University of India, Hyderabad (Italy), October 23rd-31st, 1998.
9. *Economics of Combinatorial Technologies*, *Natural Products and Combinatorial Technologies* and *Synthetic Organic Combinatorial Libraries* in the *Workshop on Combinatorial Technologies and Natural Products*, ICS-UNIDO and University of the Philippines, Los Banos (Philippines), April 19th-23rd, 1999.
10. *Combinatorial Chemistry and Drug Discovery: Many Formats for the Same Goal* in the

First International Combinatorial Chemistry Symposium (ICCS), Tubingen (Germany), October 3rd-6th, 1999.

11. *Combinatorial Libraries of Polymers and Catalysts: Examples and Applications* in *Chemical Libraries and High Throughput Screening in Biotechnology*, Siena, November 12th, 1999.
12. *Combinatorial Chemistry and Combinatorial Technologies: Principles and Methods*, in *Training Course in Molecular Modelling and Computer Assisted Combinatorial Chemistry*, ICS-UNIDO, Trieste (Italy), November 29th- December 3rd, 1999.
13. *A Survey of Combinatorial Technology Activities in GlaxoWellcome-Italy*, Gordon Conferences, Il Ciocco (Italy), May 28th, 2000.
14. *Combinatorial Chemistry and Combinatorial Technologies: Principles and Methods*, *Synthetic Organic Combinatorial Libraries, Combinatorial Libraries of Polymers and Catalysts* and *Analytical Characterization and Quality Control of Combinatorial Libraries* in the *Workshop on Combinatorial Technologies*, ICS-UNIDO and University of Mexico, Juriquilla (Mexico), May 30th-June 2nd, 2000.
15. *Combinatorial Catalysts: Biological, Organic and Inorganic Examples,* XX Congress of the Italian Chemical Society, Rimini (Italy), June 5th, 2000.
16. *Views from Industry in Combinatorial Chemistry, Combinatorial Technologies and Molecular Modelling* in the *Expert Group Meeting on Combinatorial Chemistry, Combinatorial Technologies and Molecular Design*, ICS-UNIDO, Trieste (Italy), January 29th-30th, 2001.
17. *Combinatorial Chemistry: Principles and New Trends* in the *Workshop on Combinatorial Technologies for the Development of Novel Pharmaceutically Active Compounds*, AlfaTech and Tecnofarmaci, Roma (Italy), March 20th, 2001.
18. *Combinatorial Chemistry and Combinatorial Technologies: Principles and Methods*, *Combinatorial Technologies in Drug Discovery and Agricultural Research*, *Combinatorial Chemistry of Natural Products* in the *Workshop on Combinatorial Technologies, Natural Products and HTS*, ICS-UNIDO and University of Chulalongkorn, Bangkok (Thailand), April 23rd-27th, 2001.
19. *Chemical diversity as a driving force to design and realize synthetic strategies leading to combinatorial libraries for lead discovery and lead optimization*, in the *13th Noordwijkerhout-Camerino Symposium,* Noordwijkerhout (Holland), May 6th-11th, 2001.
20. *Combinatorial library formats, sizes and applications in Drug Discovery: a critical assessment*, in *Advanced Course of Medicinal Chemistry and National Seminar for doctorate students*, Urbino (Italy), July 1st - 5th, 2001.
21. *Chemical Diversity in Drug Discovery: a critical assessment*, in *Trends and Applications in Combinatorial Chemistry and Combinatorial Technologies*, ICS-UNIDO and Eotvos University, Budapest (Hungary), October 15th-18th, 2001.
22. *Combinatorial Technologies in biopharmaceutical research*, in *Normative Comunitarie e Conseguenti Assetti Regolatori della Gestione delle Attivita´ dell´Industria Farmaceutica. Problematiche Brevettuali*, Formit, Roma (Italy), February 18th-22nd, 2002.
23. *Combinatorial Chemistry and Technologies: Basic Principles and New Trends,* in the *Training Course on Molecular Design and Computer-Assisted Combinatorial Chemistry,* ICS-UNIDO, Trieste (Italy), July 9th-12th, 2002.
24. Molecular Diversity in Drug Discovery: A Critical Assessment, in *Trends and Applications in Combinatorial Chemistry and Combinatorial Technologies*, ICS-UNIDO and Federal University of Sao Carlos, Sao Pedro (Brasil), November 20th-23rd, 2002.
25. *Sirenade Pharmaceuticals: Company Presentation*, in the *Emerging Companies Seminar*, *BIO2004*, San Francisco, 2004.
26. *Combinatorial Chemistry and Technologies: Basic Principles and New Trends,* in the *Training Course on Molecular Design and Computer-Assisted Combinatorial Chemistry,* ICS-UNIDO, Trieste (Italy), July 6th-8th, 2004.
27. *Combinatorial Chemistry and Technologies: Applications to Natural Products Research,* in the *Training Course on Molecular Design and Computer-Assisted Combinatorial Chemistry,* ICS-UNIDO, Trieste (Italy), July 6th-8th, 2004.
28. *Exploitation of Biodiversity Using Combinatorial Technologies and Molecular Design* in the *Expert Group Meeting on Combinatorial Chemistry, Combinatorial Technologies and Molecular Design*, ICS-UNIDO, Trieste (Italy), October 14th-15th, 2004.
29. *NiKem Research: Company Presentation*, at the *IX Biotech and Finance Forum*,

Europe Unlimited, Munich (D), June 2005.

30. *Diversity-Oriented Synthesis of Linear and Cyclic Peptidomimetic Libraries with Biological Activity*, in the *EUROCOMBI-3 Chemistry Conference,* Winchester (UK), July 18th-21st, 2005.
31. *Diversity-Oriented Synthesis of Linear and Cyclic Peptidomimetic Libraries with Biological Activity*, in the *High-Throughput Chemistry and New Technologies Subject Group,* Royal Society of Chemistry, Southampton (UK), July 22nd, 2005.
32. *NiKem Research: Company Presentation*, at the *X Biotech and Finance Forum*, Europe Unlimited, Barcelona (E), December 1st, 2005.
33. *Chemical Biology in Italy*, in the *Statusseminar on Chemical Biology*, DECHEMA, Frankfurt (D), December 5th-6th, 2005.
34. *Combinatorial Technologies in the exploitation of biodiversity*, in the *Expert Group Meeting on Project Networking*, ICS-UNIDO, Trieste (I), December 12th- 13th, 2005.
35. *High Quality Medchem: A Key Value in the Shifting R&D Paradigm*, in the *European School of Medicinal Chemistry (ESMEC) 2006*, Urbino (Italy), July 2nd-6th, 2006.
36. *Combinatorial Technologies in industrial environments*, in the *Expert Group Meeting on Combinatorial Chemistry & Molecular Design Methods: Recent Developments and Applications*, ICS-UNIDO and Istituto Mexicano del Petroleo, Morales (Mexico), December 4th-6th, 2006.
37. *NiKem Research: Company Presentation*, at the *14th International Molecular Medicine Triconference*, San Francisco (US), February 27th-March 2nd, 2007.
38. *Novel Concepts in the Design of Kinase Inhibitors for the Treatment of CNS Diseases*, in the *41st IUPAC World Chemistry Congress*, Turin (Italy), August 5th- 11th, 2007.
39. *Center for Biomolecular Interdisciplinary Studies and Industrial Applications*, in *Bioforum 2007*, Milan (Italy), September 25th-26th, 2007.
40. *Overview of Combinatorial Technologies in Modern Natural Products Research* and *Case Studies Combinatorial Technologies in Modern Natural Products Research*, in the *Workshop on Combinatorial Chemistry/Technologies and Molecular Design to Exploit Natural Product Diversity*, Bangkok (Thailand), November 30th-December 4th, 2007.
41. *Introduction to Combinatorial Chemistry and Technologies: Principles and Methods* and *Application of Combinatorial Technologies in Natural Products Research*, in the *Training Course on Molecular Design and Computer-Assisted Combinatorial Chemistry*, Douala (Cameroon), December 10th-14th, 2007.
42. *Novel Concepts in the Design of Kinase Inhibitors as Treatments for CNS Diseases*, in the *Second European Workshop in Drug Synthesis (II EWDSy)*, Siena (Italy), May 25th-30th, 2008.
43. *Introduction to Combinatorial Chemistry and Technologies: Principles and Methods,* in the *Training Course on Molecular Design and Computer-Assisted Combinatorial Chemistry,* ICS-UNIDO, Trieste (I), June 30th-July 2nd, 2008.
44. *Industrial Applications of Combinatorial Chemistry and Technologies: Selected Case Studies,* in the *Training Course on Molecular Design and Computer- Assisted Combinatorial Chemistry,* ICS-UNIDO, Trieste (I), June 30th-July 2nd, 2008.
45. *Modern High Throughput Technologies in Drug Design and Discovery: Solutions and Trends for Developing Countries,* in the *International Conference on Drug Design and Discovery for Developing Countries,* Jolly Hotel, Trieste (I), July 3rd- 5th, 2008.
46. *Protein-Protein Interactions in Apoptosis: the Smac-XIAP Example*, in the *European Chemical Biology Symposium (ECBI 2008),* Barcelona (Spain), July 10th-11th, 2008.
47. *Structure-based drug design of novel pro-apoptotic Smac/DIABLO mimetics for anticancer therapy*, in the *XIX National Meeting on Medicinal Chemistry (NMMC)*, Verona (Italy), September 14th-18th, 2008.
48. *Good Medicinal Chemists: A Key Value in Modern Pharmaceutical Research*, in the *8th Laboratory of Synthetic Methodologies in Medicinal Chemistry, Certosa di Pontignano*, SCI, Siena (Italy), February 15th-19th, 2009.
49. *Combinatorial Chemistry in Drug Discovery: challenges for anti-malaria drugs,* in the Workshop on Advanced Design and Development of potential Drugs against Malaria*,* Hotel Riviera, Trieste (Italy), March 9th-11th, 2009.
50. *Modern High Throughput Technologies in Drug Design and Discovery: Solutions and Trends for Developing Countries* and *Synthesis of Targeted Shikimate Derivatives*, in the *Workshop on Design and Discovery of Drugs against HIV, Dengue Fever and Avian*

Influenza, Bangkok (Thailand), May 4th-6th, 2009.

51. *Drug Discovery using Combinatorial Chemistry Approaches*, in the *2nd Conference on Drug Development for the Third World: From Computational Molecular Biology to Experimental Approaches*, ICTP, Trieste (Italy), June 1st-5th, 2009.
52. *Structure-based drug design of novel pro-apoptotic Smac/DIABLO mimetics for anticancer therapy*, in the 5th Annual Drug Discovery Chemistry Meeting, CHI, San Diego (CA), April 27th-29th, 2010.
53. *Proapoptotic Smac/Diablo mimetics for anticancer therapy: Structure-based drug design*, in the Third European Workshop in Drug Synthesis/EWDS, Siena, Italy, May 23rd-27th, 2010.
54. *Structure-based drug design of novel mono- and dimeric pro-apoptotic Smac/DIABLO mimetics for anticancer therapy*, in the 20th Molecular Medicine Tri-Con – Mastering Medicinal Chemistry stream, CHI, San Francisco (CA), US, February 12th-15th, 2013.
55. *Innovative chemical strategies to develop pro-apoptotic compounds*, in the "Cell Death and Disease" Workshop, Menaggio (CO), Italy, June 19th-22nd, 2013.
56. *Novel pro-apoptotic agents: chemistry-driven design, synthesis and characterization,* in the 2nd Workshop - Chemical Approaches to Targeting Drug Resistance in Cancer Stem Cells, COST Action 1106, Puerto de la Cruz, Spain, October 14th-15th, 2014.
57. *Rational design, parallel synthesis and biological characterization of Smac peptidomimetics as pro-apoptotic agents against cancer*, in the 5th International Applied Natural Sciences Conference (ANS2015), Jasnà, Slovakia, September 30th-October 2nd, 2015.
58. *Function-oriented Synthesis (FOS), Rational Design and Serendipity: The AZA-tanshinone Story*, in the 5th Drug Discovery & Therapy World Conference (DDTWC), Boston, US, July 10th-13th, 2017.

31 Marzo 2022